Shao et al. showed that dual anti-VEGF and anti-IGF1R treatment (bevacizumab and cixutumumab, respectively) enhanced tumor growth inhibition in ovarian cancer cells and provided significant benefit over either treatment alone (69). The gene discussed is IGF1R; the disease is neoplasm.